LUCY
Price
$0.86
Change
-$0.01 (-1.15%)
Updated
Oct 22 closing price
Capitalization
7.41M
21 days until earnings call
Intraday BUY SELL Signals
XWEL
Price
$0.68
Change
-$0.02 (-2.86%)
Updated
Oct 22 closing price
Capitalization
5.87M
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LUCY vs XWEL

LUCY vs XWEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LUCY vs. XWEL commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LUCY is a StrongBuy and XWEL is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LUCY with price predictions
Oct 22, 2026

LUCY's RSI Oscillator recovers from oversold territory

The RSI Oscillator for LUCY moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 32 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 63 cases where LUCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

Following a +8.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUCY advanced for three days, in 115 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

LUCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUCY as a result. In 76 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for LUCY turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 36 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

LUCY moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LUCY crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LUCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.075) is normal, around the industry mean (4.961). P/E Ratio (-0.742) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.450) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. LUCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for XWEL with price predictions
Oct 22, 2026

XWEL sees MACD Histogram just turned negative

XWEL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 44 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XWEL as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 50-day moving average for XWEL moved below the 200-day moving average on September 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XWEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for XWEL entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XWEL's RSI Indicator exited the oversold zone, 38 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +17.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where XWEL advanced for three days, in 161 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

XWEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.167) is normal, around the industry mean (66.046). P/E Ratio (-0.131) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.220) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. XWEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XWEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

FUNDAMENTALS RATINGS
XWEL: Fundamental Ratings
XWEL
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LUCYXWEL
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (LUCY: $0.87 vs. XWEL: $0.70)
Brand notoriety: LUCY and XWEL are both not notable
LUCY represents the Pharmaceuticals: Other, while XWEL is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: LUCY: 2% vs. XWEL: 629%
Market capitalization -- LUCY: $7.41M vs. XWEL: $5.87M
LUCY [@Pharmaceuticals: Other] is valued at $7.41M. XWEL’s [@Medical Specialties] market capitalization is $5.87M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $156.8B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.3B. The average market capitalization across the [@Medical Specialties] industry is $20.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LUCY’s FA Score shows that 1 FA rating(s) are green while XWEL’s FA Score has 1 green FA rating(s).

  • LUCY’s FA Score: 1 green, 4 red.
  • XWEL’s FA Score: 1 green, 4 red.
According to our system of comparison, LUCY is a better buy in the long-term than XWEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LUCY’s TA Score shows that 4 TA indicator(s) are bullish while XWEL’s TA Score has 4 bullish TA indicator(s).

  • LUCY’s TA Score: 4 bullish, 6 bearish.
  • XWEL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, XWEL is a better buy in the short-term than LUCY.

Price Growth

LUCY (@Pharmaceuticals: Other) experienced а +3.93% price change this week, while XWEL (@Medical Specialties) price change was -4.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.

Reported Earning Dates

LUCY is expected to report earnings on Nov 12, 2026.

XWEL is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+0.74% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-3.15% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
LUCY
Daily Signal:
Gain/Loss:
XWEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

LUCY and

Correlation & Price change

A.I.dvisor tells us that LUCY and XWEL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LUCY and XWEL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LUCY
1D Price
Change %
LUCY100%
-0.78%
XWEL - LUCY
29%
Poorly correlated
-2.45%
NEPH - LUCY
27%
Poorly correlated
-1.95%
WRBY - LUCY
24%
Poorly correlated
+0.16%
HBIO - LUCY
23%
Poorly correlated
-1.77%
BNGO - LUCY
23%
Poorly correlated
-5.60%
More

XWEL and

Correlation & Price change

A.I.dvisor tells us that XWEL and LUCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and LUCY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XWEL
1D Price
Change %
XWEL100%
-2.45%
LUCY - XWEL
29%
Poorly correlated
-0.78%
DRIO - XWEL
28%
Poorly correlated
-5.98%
XRAY - XWEL
23%
Poorly correlated
+4.63%
NVCR - XWEL
22%
Poorly correlated
-3.14%
MBAI - XWEL
21%
Poorly correlated
-8.97%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FWRG11.560.43
+3.86%
First Watch Restaurant Group
WING120.870.92
+0.77%
Wingstop
SIF20.17-0.83
-3.95%
SIFCO Industries
YJ1.39-0.06
-4.14%
Yunji Inc
MTSI229.73-43.32
-15.87%
MACOM Technology Solutions Holdings